In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a low estimate of $840.00.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, ... Our analyst team just revealed what they believe are the 10 best stocks to buy right now.

Eli Lilly To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday. Story by Avi Kapoor • 4w. T op Wall Street analysts changed their outlook on these top names.

Chris Shibutani, an analyst from Goldman Sachs, maintained the Hold rating on Eli Lilly & Co (LLY – Research Report). The associated price target is $650.00. Geoff Meacham has given his Hold ...

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall within a range of $13.02 and $13.52 (the previous forecast was $16.10 to ...

Eli Lilly shares were 0.7% lower at $699.40 per share as of about 1:30 p.m. ET Tuesday. They have more than doubled in value over the past year amid the buzz surrounding its weight-loss drugs.

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...

Analysts surveyed by FactSet expected $13.93 billion. Eli Lilly expects 2025 revenue between $58 billion and $61 billion. The company sees 2024 revenue around $45 billion, 32% above sales from the ...

(RTTNews) - Drugmaker Eli Lilly and Co. (LLY) reported Thursday that net income for the first quarter increased about 40 percent to $1.90 billion or $2.10 per share from $1.36 billion or $1.49 per ...

Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $964.46, a high estimate of $1125.00, and a low estimate of $884.00.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 ...